Virogates

15.45 DKK

Less than 1K followers

VIRO

First North Denmark

Medical Equipment & Services

Health Care

Overview

Financials & Estimates

Ownership

Investor consensus

-1.28 %

+17.94 %

+58.95 %

+69.78 %

+45.75 %

+4.39 %

-61.17 %

-77.74 %

-76.57 %

Virogates is active in medical technology. The company is active in research and development of biomarkers and diagnostic instruments for the healthcare industry. The products are sold under various brands and are used in the identification, analysis and further treatment of diseases, primarily cardiovascular diseases, cancer and neurological diseases. The company was established in 2001 and is headquartered in Birkerød.

Market cap

143.45M DKK

Turnover

-

Revenue

4.9M

EBIT %

-297.14 %

P/E

-

Dividend yield-%

-

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

All

Research

Press releases

3rd party

ShowingAll content types

Regulatory press release11/28/2025, 2:39 PM

ViroGates’ capital raise of DKK 19.3 million and issue of 1,547,412 shares have been registered and settled

Regulatory press release11/20/2025, 1:30 PM

suPAR Remedy, LLC announces the Completion of the public tender offer to the shareholders of ViroGates.

Regulatory press release11/18/2025, 6:41 AM

ViroGates announces a directed issue of nominally 1,547,412 shares, raising approximately DKK 19.3 million

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Regulatory press release11/17/2025, 10:31 PM

ViroGates announces a plan to offer new shares through a directed issue without preemptive rights for existing shareholders

Regulatory press release11/12/2025, 7:40 AM

suPAR Remedy, LLC announces the outcome of the Public Tender Offer to the shareholders of ViroGates.

Regulatory press release11/6/2025, 12:34 PM

ViroGates announces its Interim Report for Q1-Q3 2025

Regulatory press release10/23/2025, 1:29 PM

ViroGates announces Notice of Potential Equity / Capital Raise

Regulatory press release10/17/2025, 12:36 PM

ViroGates Receives FDA Feedback on 513(g) Request, confirming Regulatory Pathway for U.S. Market Entry

Regulatory press release10/15/2025, 1:22 PM

ViroGates announces the publication of a Board Statement in relation to the Tender Offer from suPAR Remedy, LLC

Regulatory press release10/10/2025, 6:52 AM

ViroGates announces the receipt of an Announcement and Official Tender Offer Document from suPAR Remedy LLC

Regulatory press release10/8/2025, 6:53 AM

suPAR Remedy, LLC announces public tender offer to the shareholders of ViroGates A/S at a 40% premium

Regulatory press release8/21/2025, 9:25 AM

ViroGates announces its Half-Year Report for H1 2025

Press release6/16/2025, 1:30 PM

ViroGates and GENSPEED achieve proof of concept for their suPARnostic® POC+ targeted at the Longevity Testing Market

Regulatory press release5/21/2025, 2:16 PM

Resolutions from the Extraordinary General Meeting of ViroGates A/S

Regulatory press release5/6/2025, 9:55 AM

ViroGates gives notice to convene an Extraordinary General Meeting on 21 May 2025

Regulatory press release5/1/2025, 3:39 PM

ViroGates announces its Q1 report for 2025

Regulatory press release4/24/2025, 7:17 PM

Resolutions from the Annual General Meeting of ViroGates A/S

Regulatory press release4/7/2025, 11:25 AM

Notice to convene the annual general assembly

Regulatory press release3/20/2025, 6:23 PM

ViroGates announces its Annual Report 2024

Regulatory press release3/19/2025, 5:46 PM

ViroGates announces an amendment to its agreement with Sobi

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.